Physician profile
James W Mattern
NPI 1104973205
$6,529.54
in general payments reported to CMS, 2019-2025
22 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $357 · 2021: $496 · 2022: $916 · 2023: $1,448 · 2024: $1,172 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585 · Entertainment: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,585.42 |
| Entertainment | $133.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,681.93 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Sight Sciences, INC. | $1,481.42 | 2020-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $1,213.88 | 2022-2025 | |
| Allergan, INC. | $307.34 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $253.58 | 2019 | |
| New World Medical,INC. | $217.18 | 2023 | |
| Dompe US, INC. | $203.42 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $176.91 | 2019-2023 | Cequa |
| Optos, INC. | $133.14 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $117.89 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $114.85 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $109.12 | 2025 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $93.88 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $90.43 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $67.45 | 2023 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $55.50 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $51.66 | 2025 | Syfovre |
| Glaukos Corporation | $47.30 | 2025 | Idosetr |
| Oyster Point Pharma, INC. | $40.93 | 2023-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.86 | 2019-2020 | |
| Rxsight INC | $20.42 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Light Adjustable Lens (Rxlal) |
| Ocular Therapeutix, INC. | $15.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mattern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.